RAC ASX News

29 July 2024

Bisantrene Phase 2 AML Trial Successful Concludes

Race Oncology's Phase 2 trial of bisantrene for AML meets efficacy criteria.

Race Oncology Bisantrene AML Clinical Trials Stock Market News

Posted on: 29/07/2024

Read More

23 July 2024

Quarterly Activity Report and Appendix 4C

Race Oncology announces key advancements in RC220 bisantrene development.

Race Oncology RC220 bisantrene FDA Designation Clinical Trials Stock Market News

Posted on: 23/07/2024

Read More